Adicet Bio (NASDAQ:ACET) Given Neutral Rating at HC Wainwright

Adicet Bio (NASDAQ:ACET - Get Free Report)'s stock had its "neutral" rating restated by HC Wainwright in a report issued on Friday,Benzinga reports.

A number of other equities research analysts also recently commented on the company. Wedbush reaffirmed an "outperform" rating and issued a $5.00 price objective on shares of Adicet Bio in a research report on Thursday, November 7th. StockNews.com lowered Adicet Bio from a "hold" rating to a "sell" rating in a research note on Tuesday, November 19th. Finally, JMP Securities reaffirmed a "market perform" rating on shares of Adicet Bio in a research note on Thursday, February 6th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat, Adicet Bio currently has an average rating of "Hold" and a consensus price target of $7.50.

Adicet Bio Price Performance

NASDAQ:ACET traded up $0.03 during trading hours on Friday, reaching $0.79. 175,913 shares of the company traded hands, compared to its average volume of 868,068. Adicet Bio has a 1-year low of $0.74 and a 1-year high of $2.51. The stock has a market cap of $64.99 million, a P/E ratio of -0.46 and a beta of 1.97. The firm's 50-day moving average is $0.93 and its 200-day moving average is $1.14.

Remove Ads

Adicet Bio (NASDAQ:ACET - Get Free Report) last posted its quarterly earnings data on Thursday, March 6th. The company reported ($0.32) EPS for the quarter, topping analysts' consensus estimates of ($0.37) by $0.05. As a group, research analysts predict that Adicet Bio will post -1.39 earnings per share for the current year.

Hedge Funds Weigh In On Adicet Bio

Several hedge funds and other institutional investors have recently modified their holdings of the company. GSA Capital Partners LLP increased its position in Adicet Bio by 161.3% during the 3rd quarter. GSA Capital Partners LLP now owns 39,208 shares of the company's stock worth $56,000 after purchasing an additional 24,203 shares in the last quarter. FMR LLC grew its stake in Adicet Bio by 31.3% during the third quarter. FMR LLC now owns 276,169 shares of the company's stock worth $398,000 after buying an additional 65,903 shares during the period. RBF Capital LLC increased its position in shares of Adicet Bio by 62.5% in the third quarter. RBF Capital LLC now owns 601,135 shares of the company's stock worth $866,000 after acquiring an additional 231,135 shares in the last quarter. XTX Topco Ltd raised its stake in shares of Adicet Bio by 12.5% in the 3rd quarter. XTX Topco Ltd now owns 292,180 shares of the company's stock valued at $421,000 after acquiring an additional 32,392 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Adicet Bio by 14.5% during the 3rd quarter. Geode Capital Management LLC now owns 768,566 shares of the company's stock valued at $1,107,000 after acquiring an additional 97,567 shares in the last quarter. 83.89% of the stock is owned by institutional investors and hedge funds.

Adicet Bio Company Profile

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.